Drug recall · October 28, 2020
Candesartan Cilexetil and Hydrochlorothiazide Tablets recall
Why: Out-of-specification organic impurity results obtained during routine stability testing.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Candesartan Cilexetil and Hydrochlorothiazide Tablets, USP 32 mg/12.5 mg, packaged in a) 90-count bottles (NDC 0378-3002-77) and b) 500-count bottles (NDC 0378-3002-05), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.
- Lots / codes
Lot #: a) 8095666, Exp. Date July 2021 b) 3104664, Exp. Date July 2021
- Quantity
- 10,695 bottles
- Company
- Mylan Pharmaceuticals Inc., Morgantown, WV
- Distribution
- Nationwide within the United States
- Initiated
- October 2, 2020 · Voluntary: Firm initiated
- Classified
- October 22, 2020
- Reported
- October 28, 2020
- Ended
- January 24, 2022
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Candesartan / hydrochlorothiazide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.